Blockade of CD40–TRAF2,3 or CD40–TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells

Inhibition of the CD40–CD154 pathway controls inflammatory disorders. Unfortunately, administration of anti-CD154 monoclonal antibodies causes thromboembolism. Blockade of signalling downstream of CD40 may represent an approach to treat CD40-driven inflammatory disorders. Blocking tumour necrosis fa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Immunology
Asıl Yazarlar: Portillo, Jose-Andres C, Greene, Jennifer A, Schwartz, Isaac, Subauste, Maria Cecilia, Subauste, Carlos S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Science Inc 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4264907/
https://ncbi.nlm.nih.gov/pubmed/25051892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.12361
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller